FDA Withdraws Approval of Pepaxto for Multiple Myeloma : vim

The FDA has made the final decision to withdraw the approval of Pepaxto (melphalan flufenamide) for multiple myeloma.

Related Keywords

Peter Marks , Drug Administration , Biologics Evaluation , Research Director Peter Marks ,